| Document Date: 2013-06-24 05:53:12
Open Document File Size: 79,42 KBShare Result on Facebook
City Tokyo / Injection Northbrook / Northbrook / / Company Astellas Pharma Inc. / Astellas Pharma US Inc. / / Country United States / / / Event FDA Phase / / Facility University of California / Children’s Hospital of Orange County / / IndustryTerm immune systems / pharmaceutical / pediatric healthcare professionals / pharmaceutical products / / MedicalCondition esophageal candidiasis / headache / osteomyelitis / nausea / anaphylaxis / thrombocytopenia / invasive candidiasis / hypersensitivity / diarrhea / older included vomiting / hepatitis / illness / pruritus / renal dysfunction / infections / bloodstream infection / common fungal infections / Pediatric Infectious Diseases / abdominal pain / hemolytic anemia / shock / Candida Infections / abscesses / serious hypersensitivity / vomiting / Acute Disseminated Candidiasis / hepatic failure / endocarditis / candidemia / acute disseminated candidiasis / infection / rash / meningitis / clinically significant hepatic dysfunction / acute renal failure / / MedicalTreatment intravenous infusion / / Organization Children’s Hospital of Orange County and Clinical / University of California / Irvine / U.S. Food and Drug Administration / FDA / / Person Sef Kurstjens / Jenny Kite / Candida Peritonitis / Antonio C. Arrieta / / / Position Professor / Pediatrics / global category leader / chief medical officer / Director / / Product Supplemental New Drug Application (sNDA) / MYCAMINE / MYCAMINE® (micafungin sodium) / / ProvinceOrState Illinois / California / Orange County / / URL www.astellas.us / /
SocialTag |
Microsoft Word - Mycamine Pediatric_Press Release FINALv2.docx